News Sentiment

NPCE sentiment intelligence

Neuropace Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 55 Balanced news tone 57 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Medical Devices Read-through group
Latest close 17.11 Week of 10 Jul 2026
Weighted tone 55/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

75/100 classification confidence.

Company focus 46

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend active

+6.0% over one week, +9.4% over four weeks, trend active, and materially above fair value.

Latest direct headline Positive

Here's Why You Should Retain NeuroPace Stock in Your Portfolio for Now

Market Reaction

Price moving ahead of tone

62/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 75/100 classification
One-week reaction 6.0% Price confirming higher
Trend fit Trend active 9.4% over four weeks
Fair value 51.7% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 16
Neutral 38
Negative 3

Relevance

Why the article matched

Direct first
Direct company coverage 46
Industry context 11
Sector context 0

Sources

Coverage mix

Publishers
Market source 13
TradingView 6
Stock Titan 6
TradingKey 6
MarketBeat 3
Finviz 2
Stock Traders Daily 2
StockStory 2

Event Lens

What the news is about

Classified themes
Earnings 25
Market update 23
Analyst action 3
Regulatory and legal 3
Balance sheet 1
Deals and strategy 1
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-57 of 57
TradingView Direct company coverage

Here's Why You Should Add NeuroPace Stock to Your Portfolio Now

NeuroPace, Inc. (NPCE) is poised for significant growth, driven by the strong adoption of its RNS System, expanding referral networks, and AI-driven innovations aimed at improving efficiency in epilepsy treatment. The potential FDA approval for idiopathic generalized epilepsy (IG

Tone
Positive 71/100
Event
Regulatory and legal
Published
10 Jun 2026 14:39
Source
TradingView
Minichart Direct company coverage

NeuroPace, Inc. Files Form 8-K Reporting 2026 Annual Meeting Results and Company Information

NeuroPace, Inc. filed Form 8-K to report the results of its 2026 Annual Meeting, held virtually on June 5, 2026. Shareholders re-elected two Class II directors and ratified PricewaterhouseCoopers LLP as the independent registered public accounting firm, showing strong support for

Tone
Positive 60/100
Event
Earnings
Published
09 Jun 2026 17:49
Source
Minichart
Zacks Investment Research Direct company coverage

Should I buy NeuroPace (NPCE)

Tone
Positive 66/100
Event
Market update
Published
24 Apr 2021 23:14
Source
Zacks Investment Research